Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27310914 | 0.96 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL3821278 | 0.87 | IDUA (0.31) | — | |
| SCHEMBL28093271 | 0.87 | IDUA (0.31) | — | |
| SCHEMBL9556151 | 0.85 | — | — | |
| SCHEMBL28641674 | 0.83 | — | — | |
| SCHEMBL25379088 | 0.82 | — | — | |
| SCHEMBL28242019 | 0.82 | IDUA (0.32) | — | |
| SCHEMBL27966923 | 0.80 | — | — | |
| SCHEMBL28064418 | 0.79 | — | — | |
| SCHEMBL185267 | 0.79 | LGALS3 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112601555-A | Compositions and methods relating to anti-CD 19 antibody drug conjugates | 乐高化学生物科学股份有限公司 | 2021-04-02 | — | — | CN | claimed |
| EP-4635501-A2 | SAPONIN DERIVATIVES WITH IMPROVED THERAPEUTIC WINDOW | Sapreme Technologies B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| EP-4003427-B1 | SAPONIN DERIVATIVES WITH IMPROVED THERAPEUTIC WINDOW | SAPREME TECH BV (NL) | 2025-09-17 | — | — | EP | disclosed |
| EP-4282853-A1 | PROCESS FOR THE PREPARATION OF MESACONIC ACID ESTERS | Symrise AG (DE) | 2023-11-29 | — | — | EP | disclosed |
| US-20230365617-A1 | SAPONIN DERIVATIVES FOR USE IN MEDICINE | SAPREME TECHNOLOGIES B.V. (NL) | 2023-11-16 | — | — | US | disclosed |
| CN-115551537-A | Tumor cell vaccine | 纽沃进公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115461461-A | MiRNA-193a for promoting immunogenic cell death | 因特尔纳技术有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-110099990-B | Perfume mixture | 西姆莱斯股份公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-115322833-A | Perfume mixture | 西姆莱斯股份公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115315434-A | Interleukin 15 fusion proteins and prodrugs and compositions and methods thereof | 免疫靶向有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-110709392-A | Isoquinoline as HPK1 inhibitors | 豪夫迈·罗氏有限公司 | 2020-01-17 | — | — | CN | disclosed |
| CN-110678466-A | Naphthyridines as HPK1 inhibitors | 豪夫迈·罗氏有限公司 | 2020-01-10 | — | — | CN | disclosed |
| EP-3559179-A1 | FRAGRANCE MIXTURE | Symrise AG (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-8404650-B2 | Methods of treating cancer with doxazolidine and prodrugs thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110135618-A1 | METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2007102888-A2 | METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2007-09-13 | — | — | WO | disclosed |
| US-7037907-B1 | Estradiol conjugates and uses thereof | THE UNIVERSITY OF MELBOURNE (AU) | 2006-05-02 | — | — | US | disclosed |
| EP-1226154-A4 | ESTRADIOL CONJUGATES AND USES THEREOF | UNIV MELBOURNE (AU) | 2005-03-23 | — | — | EP | disclosed |
| EP-1226154-A1 | ESTRADIOL CONJUGATES AND USES THEREOF | THE UNIVERSITY OF MELBOURNE (AU) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001027132-A1 | ESTRADIOL CONJUGATES AND USES THEREOF | THE UNIVERSITY OF MELBOURNE (AU) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365617-A1 | SAPONIN DERIVATIVES FOR USE IN MEDICINE | HAVCR2, TTR, PYGL | ALDH1A1 1485/4885TSHR 182/4885HSD17B10 677/4885 |
| US-20110135618-A1 | METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF | DNPEP, PEPD, PREP | ALDH1A1 427/4885TSHR 3888/4885HSD17B10 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.